Faculty Profiles - SONE, Hirohito

Papers - SONE, Hirohito

Division display 61 - 80 of about 657 ／ All the affair displays >>

1372-P: Association between Fat Intake as the Percent of Total Energy and Incidence of Cardiovascular Disease in Persons with Type 2 Diabetes—Japan Diabetes Complication and Its Prevention Prospective Study (JDCP Study)

CHIKA HORIKAWA, MITSUYOSHI TAKAHARA, NAOTO KATAKAMI, YASUNAGA TAKEDA, MIZUKI TAKEUCHI, KAZUYA FUJIHARA, HIROAKI SUZUKI, NARIHITO YOSHIOKA, HITOSHI SHIMANO, JO SATOH, YASUAKI HAYASHINO, NAOKO TAJIMA, RIMEI NISHIMURA, YOSHIMITSU YAMASAKI, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Previous systematic reviews showed benefits of low-carbohydrate eating plans compared with low-fat eating plans in the treatment of diabetes (T2D) on parameters of cardiovascular disease (CVD) risk. However, studies on the relationship between fat intake as the % of total energy (F%E) and incidence of CVD in persons with T2D are insufficient. Therefore, we investigated this relationship as part of the JDCP study, a nationwide study launched in 2007. A total of 1477 persons with T2D aged 40-75 years completed a brief self-administered Diet History Questionnaire at baseline, and we analyzed the resultant data. Primary outcome was the 7-year risk of a CVD event. Hazard ratios for CVD according to quartiles of F%E (Q1-4) were estimated by Cox regression adjusted for confounders including sex, age, various laboratory tests, medication use, smoking history, drinking habits, physical activity, energy intake, protein intake, dietary fiber intake, and sodium intake. Mean F%E in Q1 to Q4 were 16.6%E, 21.8%E, 25.4%E, and 30.9%E, respectively. HbA1c, body mass index, triglycerides, and blood pressure were well controlled. No significant associations between F%E and incidence of CVD were shown for Q2, Q3, and Q4 relative to Q1 (Q2: 1.03 [95% CI, 0.47-2.28], Q3: 1.27 [0.58-2.76], and Q4: 1.10 [0.44-2.73]). Stratified analysis by sex and age also showed no significant difference between F%E and incidence of CVD. When %E from saturated fatty acids (SFA%E) was analyzed according to quartiles 1 and 4 SFA%E values were 4.9%E and 7.1%E, respectively. There were no significant differences in incidence of CVD among quartiles (Q1: Reference, Q2: 1.31 [0.66-2.61], Q3: 0.47 [0.18-1.25], and Q4: 1.02 [0.44-2.39]). Findings suggested that most Japanese with T2D during the study period consumed &lt; 30% of F%E and &lt;10% of SFA%E. No significant differences in incident CVD were observed within these ranges.

Disclosure

C. Horikawa: None. M. Takahara: None. N. Katakami: Speaker's Bureau; Abbott Japan Co., Ltd., Kowa Company, Ltd., MSD, Mitsubishi Tanabe Pharma Corporation, Lilly Diabetes, Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Kyowa Kirin Co., Ltd., Daiichi Sankyo, Boehringer-Ingelheim, Sanofi. Y. Takeda: None. M. Takeuchi: None. K. Fujihara: None. H. Suzuki: Speaker's Bureau; Abbott Japan Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk, Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Boehringer-Ingelheim, Terumo Corporation, AstraZeneca, Bayer Inc., Kyowa Kirin Co., Ltd. N. Yoshioka: None. H. Shimano: None. J. Satoh: Speaker's Bureau; Lilly Diabetes, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Boehringer-Ingelheim. Y. Hayashino: Speaker's Bureau; Eli Lilly and Company, Merck & Co., Inc., Boehringer-Ingelheim, Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk A/S. N. Tajima: None. R. Nishimura: Speaker's Bureau; Abbott. Advisory Panel; Abbott Japan Co., Ltd. Speaker's Bureau; Boehringer-Ingelheim, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Medtronic, Sanofi, Taiho Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Eli Lilly and Company, Novo Nordisk A/S. Consultant; Terumo Corporation. Y. Yamasaki: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

Funding

The Japan Diabetes Society, the Japan Society for the Promotion of Science(23K10873).

DOI： 10.2337/db24-1372-p

researchmap

1666-P: Effect of Obesity in Family History (FH) on the Prevalence of Type 2 Diabetes Mellitus (T2DM), Hypertension (HT), and Dyslipidemia (DL)

IZUMI IKEDA, KAZUYA FUJIHARA, YASUNAGA TAKEDA, CHIKA HORIKAWA, SATORU KODAMA, EFREM D. FERREIRA, YASUMICHI MORI, TAKASHI KADOWAKI, RITSUKO YAMAMOTO-HONDA, YASUJI ARASE, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Heritability and obesity are strongly associated with the prevalence of T2DM, HT, and DL. We compared the effects of an FH of T2DM, HT, and DL combined with obesity on the prevalence of each in the same population. Of 41931 participants who underwent health checkups, the effects of an FH and BMI on the prevalence of those conditions were analyzed cross-sectionally. Prevalences of T2DM, HT, and DL were 5%, 20%, and 48%, respectively. Logistic regression analysis showed that ORs increased for all three as the number of FH positive cases increased and was most pronounced for T2DM. An FH of obesity and increased BMI were additively associated with the prevalence of the three diseases compared to BMI 20.0-21.9 and no positive FH (Fig. A). In addition, the combination of the number of family members with FH positivity (0,1, 2, ≥3) and obesity was additively associated with an increased FH of the three diseases compared to non-obesity and no FH of any of these diseases (Fig. B). For T2DM, the OR increased sharply in non-obese participants when the number of those with an FH of T2DM was ≥3 (14.4 [8.88-23.5]), but in obese participants the OR increased sharply when the number of those with an FH of T2DM was 2 (12.2 [8.85-16.9]) (Fig. B). Results suggest that, especially for T2DM, avoidance of obesity may be effective in reducing the prevalence of these disorders in those with many FH-positive family members.

 Disclosure

I. Ikeda: None. K. Fujihara: None. Y. Takeda: None. C. Horikawa: None. S. Kodama: None. E.D. Ferreira: None. Y. Mori: None. T. Kadowaki: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1666-p

researchmap

1148-P: Trajectories of Abnormalities in Metabolic Parameters in Japanese Adolescents and Young Adults

IZUMI IKEDA, KAZUYA FUJIHARA, HARUKA SHIOZAKI, SAKIKO Y. MORIKAWA, CHIKA HORIKAWA, YASUNAGA TAKEDA, HAJIME ISHIGURO, TAKAHO YAMADA, SATORU KODAMA, YOHEI OGAWA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Childhood obesity mostly transitions into adulthood and leads to non-communicable diseases such as type 2 diabetes and metabolic syndrome. We aimed to examine individual-level transitions in metabolic parameters during adolescence and young adulthood. We analyzed metabolic parameters in 523 participants (311 males) who underwent health examinations at the ages of 14 y (8th grade) and 20 y. Weight status was assessed by the International Obesity Task Force at 14 y and by BMI (thinness: &lt;18.5; normal: 18.5-24.9; obesity: ≥25.0) at 20 y. HbA1c ≥5.7% was defined as high. Clustered metabolic risk score (CMR) was calculated by summing the sex-age specific Z-scores of each metabolic factor (mean arterial pressure, non-HDLC, and HbA1c) with ≥1 SD defined as high. Among participants who were obese at 14 y, 56% of males and 29% of females remained obese at 20 y. In both sexes, 30-50% had high HbA1c and 30-50% had high CMR as tracked from adolescence to adulthood (table). Furthermore, the high CMR of obese females increased markedly from about 20% at 14 y to 50% at 20 y. In addition, 60% of females who were obese at both 14 y and 20 y had high HbA1c at 20 y. Results suggested the importance of lifestyle interventions from childhood, as about half of the high metabolic parameters observed in adolescents were tracked into adulthood, and obesity complications, which were rarely shown at 14 y, appeared in many at age 20 y.

 Disclosure

I. Ikeda: None. K. Fujihara: None. H. Shiozaki: None. S.Y. Morikawa: None. C. Horikawa: None. Y. Takeda: None. H. Ishiguro: None. T. Yamada: None. S. Kodama: None. Y. Ogawa: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1148-p

researchmap

1264-P: Impacts of Diabetes (DM) on Severe Functional Disability (FD) and Care-Need Level Deterioration in Japanese

IZUMI IKEDA, KAZUYA FUJIHARA, HARUKA SHIOZAKI, SAKIKO Y. MORIKAWA, KAHORI TSURUOKA, YAMASHITA YUKO, LAY MON KHIN, SIJIA WU, NORIKO YAGYUDA, CHIKA HORIKAWA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Avoidance of FD and the deterioration of care level needs leading to a decline in ADL and increased medical costs is urgent. We aimed to clarify the association between lifestyle habits, non-communicable diseases (i.e., DM, HT, and dyslipidemia) and their combinations and the incidence of severe FD and deterioration of the care-level. Followed for a median of 3.7 years were 9673 people who underwent health checkups. Care-level ≥2 (total assistance needed) indicates severe FD and worsening from the initial examination indicates deterioration. During the study period, 111 cases of severe FD occurred. Multivariate analysis showed that aging (per 5y) (OR 2.24 [1.95-2.56]), male (1.76 [1.16-2.66]), BMI&lt;18.5 (2.46 [1.40-4.35]), DM (1.81 [1.06-3.08]), HT (1.58 [1.05-2.38]), and lack of physical activity (PA) (2.17 [1.37-3.45]) were associated with severe FD. Prevalence of DM additively associated with severe FD. DM and ≥2 risk factors had a 10 times greater association than non-DM and no risk factor. Of 85 cases with worsening care needs, only DM was significantly associated with deterioration (2.88 [1.08-7.65]). DM is a significant risk factor for with double the increased risk of severe FD and triple care-need deterioration compared with those without DM. Also, in DM patients, low BMI, HT, and lack of PA greatly increased the risk of severe FD, suggesting the need for comprehensive treatment strategies.

 Disclosure

I. Ikeda: None. K. Fujihara: None. H. Shiozaki: None. S.Y. Morikawa: None. K. Tsuruoka: None. Y. Yuko: None. L. Khin: None. S. Wu: None. N. Yagyuda: None. C. Horikawa: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1264-p

researchmap

重度糖尿病により帯状疱疹の全身性播種を来した一例

木村智佑, 間島貴之, 佐藤隆明, 鈴木浩史, 鈴木紗也佳, 佐藤もも, 加勢夕季乃, 河合亨, 松林泰弘, 山田貴穂, 曽根博仁

新潟医学会雑誌 138 ( 6 ) 222 - 222 2024.6

Reduced chondroitin sulfate content prevents diabetic neuropathy through transforming growth factor-β signaling suppression. International journal

Hajime Ishiguro, Takashi Ushiki, Atsuko Honda, Yasuhiro Yoshimatsu, Riuko Ohashi, Shujiro Okuda, Asami Kawasaki, Kaori Cho, Suguru Tamura, Tatsuya Suwabe, Takayuki Katagiri, Yiwei Ling, Atsuhiko Iijima, Tadahisa Mikami, Hiroshi Kitagawa, Akiyoshi Uemura, Kazunori Sango, Masayoshi Masuko, Michihiro Igarashi, Hirohito Sone

iScience 27 ( 4 ) 109528 - 109528 2024.4

Language：English Publishing type：Research paper (scientific journal)

Diabetic neuropathy (DN) is a major complication of diabetes mellitus. Chondroitin sulfate (CS) is one of the most important extracellular matrix components and is known to interact with various diffusible factors; however, its role in DN pathology has not been examined. Therefore, we generated CSGalNAc-T1 knockout (T1KO) mice, in which CS levels were reduced. We demonstrated that diabetic T1KO mice were much more resistant to DN than diabetic wild-type (WT) mice. We also found that interactions between pericytes and vascular endothelial cells were more stable in T1KO mice. Among the RNA-seq results, we focused on the transforming growth factor β signaling pathway and found that the phosphorylation of Smad2/3 was less upregulated in T1KO mice than in WT mice under hyperglycemic conditions. Taken together, a reduction in CS level attenuates DN progression, indicating that CS is an important factor in DN pathogenesis.

DOI： 10.1016/j.isci.2024.109528

PubMed

researchmap

Usefulness of New Criteria for Metabolic Syndrome Optimized for Prediction of Cardiovascular Diseases in Japanese.

Yurie Yamazaki, Kazuya Fujihara, Takaaki Sato, Mayuko Harada Yamada, Yuta Yaguchi, Yasuhiro Matsubayashi, Takaho Yamada, Satoru Kodama, Kiminori Kato, Hitoshi Shimano, Hirohito Sone

Journal of atherosclerosis and thrombosis 31 ( 4 ) 382 - 395 2024.4

Language：English Publishing type：Research paper (scientific journal)

AIMS: We attempted to clarify whether the multiple criteria for metabolic syndrome (MetS) can sufficiently predict cardiovascular disease, whether waist circumference (WC) should be required, and whether sex-specific thresholds for each component are necessary. Only a few large-scale studies among East Asians have addressed the ability of MetS to predict cardiovascular disease. METHODS: We analyzed the data of 330,051 men and 235,028 women aged 18-74 years with no history of coronary artery disease (CAD) or cerebrovascular disease (CVD) from a nationwide Japanese claims database accumulated during 2008-2016. The association of each MetS component with CAD or CVD (CAD/CVD), MetS associated with CAD/CVD according to various criteria, and utility of modified criteria with more specific optimal values for each component were examined using multivariate Cox regression and receiver operating characteristic (ROC) analysis. RESULTS: During the study, 3,934 men (1.19%) and 893 women (0.38%) developed CAD/CVD. For each current MetS criteria, there was a 1.3- to 2.9-fold increased risk of CAD/CVD. Optimal thresholds for predicting CAD/CVD were WCs of 83 and 77 cm, triglycerides levels of 130 and 90 mg/dl, high-density lipoprotein cholesterol levels of 50 and 65 mg/dl, blood pressures of 130/80 and 120/80 mmHg, and fasting plasma glucose levels of 100 and 90 mg/dl for men and women, respectively. The existing MetS criteria and modified criteria were not significantly different in predicting CAD/CVD, but using the modified criteria markedly increased the prevalence of MetS and percentage of people with MetS developing CAD/CVD. CONCLUSIONS: Although various criteria for MetS similarly predicted CAD/CVD, the new criteria greatly reduced the number of high-risk individuals, especially women, overlooked by the current criteria.

DOI： 10.5551/jat.64380

PubMed

researchmap

糖尿病(DM)の有無別にみた生活習慣関連因子(Cardiovascular Health Metrics)が腎透析導入(HD)に及ぼす影響の検討

大澤妙子, 藤原和哉, 山田万祐子, 矢口雄大, 佐藤隆明, 北澤勝, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 168 2024.4

糖尿病患者における重症合併症の複合アウトカム(CSDC)の発症リスク因子の検討

田中菜々子, 矢口雄大, 佐藤隆明, 大澤妙子, 鈴木浩史, 山田貴穂, 藤原和哉, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 186 2024.4

代謝異常を伴う脂肪肝(MASLD)サブタイプのトランジションとCVD新規発症との関連について

松林泰弘, 藤原和哉, 山田万祐子, 佐藤隆明, 矢口雄大, 山本正彦, 石黒創, 大澤妙子, 北澤勝, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 215 2024.4

新規開発した総合体力指標フィジカルスコアによる各種代謝疾患の発症予測能の検討

佐藤隆明, 藤原和哉, 矢口雄大, 山本正彦, 北澤勝, 鈴木浩史, 松林泰弘, 石黒創, 大澤妙子, 山田貴穂, 加藤公則, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 216 2024.4

糖尿病予備群(preDM)におけるHbA1c,空腹時血糖(FPG)およびそれらの組み合わせによる脳心血管疾患(CVD)発症リスクの関連

村井幸四郎, 藤原和哉, 山田万祐子, 矢口雄大, 北澤勝, 山本正彦, 佐藤隆明, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 247 2024.4

メタボリックシンドローム(MetS)の経年的変化と心血管疾患発症の関連

滝澤大輝, 藤原和哉, 三ツ間友里恵, 山田万祐子, 村井幸四郎, 佐藤隆明, 矢口雄大, 山本正彦, 大澤妙子, 北澤勝, 松林泰弘, 岩永みどり, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 249 2024.4

写真撮影を含むスマートフォンアプリを用いた自由行動下での利用者及び医療者の負担を最小限とする食事記録方法の検討

北澤勝, 堀川千嘉, 長谷川美代, 武田安永, 松林泰弘, 山田貴穂, 児玉暁, 曽根博仁

日本栄養・食糧学会大会講演要旨集 78回 242 - 242 2024.4

PHRスマートフォンアプリとisCGMを連動させた2型糖尿病発症予防プログラムの有効性検証のためのランダム化比較試験

北澤勝, 武田安永, 治田麻理子, 堀川千嘉, 佐藤隆明, 大澤妙子, 石澤正博, 鈴木浩史, 松林泰弘, 藤原和哉, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 216 2024.4

日本人2型糖尿病患者における,飽和脂肪酸エネルギー比率と心血管疾患発症との関係 JDCP studyの解析から

堀川千嘉, 高原充佳, 片上直人, 武田安永, 竹内瑞希, 藤原和哉, 鈴木浩明, 津田謹輔, 吉岡成人, 島野仁, 佐藤譲, 林野泰明, 田嶼尚子, 西村理明, 山崎義光, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 169 2024.4

Decade-long WT1-specific CTLs induced by WT1 peptide vaccination.

Tatsuya Suwabe, Yasuhiko Shibasaki, Suguru Tamura, Takayuki Katagiri, Kyoko Fuse, Tori Ida-Kurasaki, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko

International journal of hematology 119 ( 4 ) 399 - 406 2024.4

Language：English Publishing type：Research paper (scientific journal)

INTRODUCTION: The peptide-based cancer vaccine targeting Wilms' tumor 1 (WT1) is a promising immunotherapeutic strategy for hematological malignancies. It remains unclear how long and to what extent the WT1-specific CD8 + cytotoxic T cell (CTL) persist after WT1 peptide vaccination. METHODS: The WT1 peptide vaccine was administered with written consent to a patient with CML in the chronic phase who did not respond well to imatinib, and the patient was followed for 12 years after vaccination. Immune monitoring was performed by specific amplification of WT1-specific CTLs using a mixed lymphocyte peptide culture. T-cell receptors (TCRs) of amplified WT1-specific CTLs were analyzed using next-generation sequencing. This study was approved by the Institutional Review Board of our institution. RESULT: WT1-specific CTLs, which were initially detected during WT1 peptide vaccination, persisted at a frequency of less than 5 cells per 1,000,000 CD8 + T cells for more than 10 years. TCR repertoire analysis confirmed the diversity of WT1-specific CTLs 11 years after vaccination. CTLs exhibited WT1 peptide-specific cytotoxicity in vitro. CONCLUSION: The WT1 peptide vaccine induced an immune response that persists for more than 10 years, even after cessation of vaccination in the CML patient.

DOI： 10.1007/s12185-024-03723-1

PubMed

researchmap

詳細な家族歴が2型糖尿病,高血圧,脂質異常症の有病と発症に与える影響の横断縦断的検討

池田和泉, 五十嵐理沙, 藤原和哉, 武田安永, 松林泰弘, 児玉暁, 山田貴穂, 森保道, 門脇孝, 本田律子, 荒瀬康司, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 194 2024.4

詳細な家族歴が2型糖尿病,高血圧,脂質異常症の有病と発症に与える影響の横断縦断的検討

池田和泉, 五十嵐理沙, 藤原和哉, 武田安永, 松林泰弘, 児玉暁, 山田貴穂, 森保道, 門脇孝, 本田律子, 荒瀬康司, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 194 2024.4

健常妊婦における妊娠初期の栄養摂取状況と体重増加量および母児の転帰の検討

谷内洋子, 山田貴穂, 柳生田紀子, 児玉暁, 龍野一郎, 曽根博仁

日本栄養・食糧学会大会講演要旨集 78回 290 - 290 2024.4

　 PREV - NEXT 　

<SONE, Hirohito>

Papers - SONE, Hirohito